GSK to acquire Biotech Growth Trust portfolio company Nuvalent for $10.6bn

BIOG

Biotech Growth Trust plc (LON:BIOG) has noted the announcement on Tuesday, 9 June 2026 that GSK plc has entered into an agreement to acquire BIOG portfolio company, Nuvalent, Inc. for $10.6 billion, or $124 per share, in cash, representing a 40% premium to Nuvalent’s closing price on Monday, 8 June 2026.

Nuvalent is a US-based biopharmaceutical company focused on developing targeted therapies for the treatment of cancer. Its two lead drugs are both under review for marketing approval and are expected to be available to treat non-small cell lung cancer patients that have specific mutations later this year.

The Company’s holdings in Nuvalent represented 1.5% of the Company’s net asset value (NAV) at the time of the announcement. The transaction will be reflected in the Company’s NAV as at close of business on Tuesday, 9 June 2026, which will be announced on Wednesday, 10 June 2026.

This follows recent acquisitions of portfolio companies Avidity Biosciences, Cidara Therapeutics, Amicus Therapeutics, Apellis Pharmaceuticals, KalVista Pharmaceuticals and Esperion Therapeutics.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Biotech Growth Trust shares rise 22.9% as five portfolio companies agree takeovers

Biotech Growth Trust recorded a 22.9% total return on its share price in the six months to September 2026,...

Biotech Growth Trust reports 16.5% annual share price return as NAV rises 16%

Biotech Growth Trust reported a 16.5% one-year total return on its share price and a 16.0% increase in NAV...

GSK secures positive EU recommendation for Bexsero Meningitis booster

GSK has received a positive recommendation from the EMA's CHMP for a Bexsero label update to include a single...

Cancer research advances bring new treatment options and improve patient outcomes

Advances in cancer research are expanding treatment options, improving early detection and developing more personalised approaches....

Drug development continues to create opportunities for medical innovation

The development of new medicines combines scientific research, clinical trials and regulatory review to bring potential treatments closer to...

The Biotech Growth Trust: Recent Sector Weakness Could Present an Opportunity, Says Kepler Partners

The Biotech Growth Trust could benefit from renewed pharmaceutical acquisitions and biotechnology innovation, according to Kepler Partners research....

Search